|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0011860,
umls-concept:C0030705,
umls-concept:C0038951,
umls-concept:C0231204,
umls-concept:C0235378,
umls-concept:C0314603,
umls-concept:C0332307,
umls-concept:C1273518,
umls-concept:C1521761,
umls-concept:C1556094,
umls-concept:C2603343
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
2003-5-6
|
|
pubmed:abstractText |
Troglitazone is a 2,4-thiazolidinedione antidiabetic agent with insulin-sensitizing activities. This agent had been used efficiently in a large number of patients but was withdrawn from the market in March 2000 because of its association with idiosyncratic hepatotoxicity. To address the susceptible genetic factors responsible for the hepatotoxicity associated with this agent, we performed a genetic polymorphic analysis by a target gene approach in troglitazone-treated Japanese patients with type 2 diabetes mellitus.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
0009-9236
|
|
pubmed:author |
pubmed-author:FurukawaHidehikoH,
pubmed-author:HaruyamaHideyukiH,
pubmed-author:IzumiTakashiT,
pubmed-author:KogaTeiichiroT,
pubmed-author:KoishiRyutaR,
pubmed-author:MatsushitaYasuyukiY,
pubmed-author:MiyoshiKaoruK,
pubmed-author:NakamuraKouichiK,
pubmed-author:ShimizuMihoM,
pubmed-author:SugawaraMieM,
pubmed-author:TakahashiTohruT,
pubmed-author:TomitaAikoA,
pubmed-author:WatanabeIchiroI,
pubmed-author:YasumoHiroakiH
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
73
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
435-55
|
|
pubmed:dateRevised |
2009-11-19
|
|
pubmed:meshHeading |
pubmed-meshheading:12732844-Aged,
pubmed-meshheading:12732844-Alanine Transaminase,
pubmed-meshheading:12732844-Alleles,
pubmed-meshheading:12732844-Aspartate Aminotransferases,
pubmed-meshheading:12732844-Chromans,
pubmed-meshheading:12732844-DNA,
pubmed-meshheading:12732844-DNA Primers,
pubmed-meshheading:12732844-Data Collection,
pubmed-meshheading:12732844-Diabetes Mellitus, Type 2,
pubmed-meshheading:12732844-Drug-Induced Liver Injury,
pubmed-meshheading:12732844-Female,
pubmed-meshheading:12732844-Gene Frequency,
pubmed-meshheading:12732844-Genotype,
pubmed-meshheading:12732844-Glutathione Transferase,
pubmed-meshheading:12732844-Humans,
pubmed-meshheading:12732844-Hypoglycemic Agents,
pubmed-meshheading:12732844-Japan,
pubmed-meshheading:12732844-Male,
pubmed-meshheading:12732844-Middle Aged,
pubmed-meshheading:12732844-Polymorphism, Genetic,
pubmed-meshheading:12732844-Sex Characteristics,
pubmed-meshheading:12732844-Thiazoles,
pubmed-meshheading:12732844-Thiazolidinediones
|
|
pubmed:year |
2003
|
|
pubmed:articleTitle |
A study to survey susceptible genetic factors responsible for troglitazone-associated hepatotoxicity in Japanese patients with type 2 diabetes mellitus.
|
|
pubmed:affiliation |
Regulatory Affairs Department, Sankyo Co, Ltd, Tokyo, Japan.
|
|
pubmed:publicationType |
Journal Article
|
